Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Simona Signorini"'
Autor:
Virginia Quaresima, Cristina Scarpazza, Alessandra Sottini, Chiara Fiorini, Simona Signorini, Ottavia Maria Delmonte, Liana Signorini, Eugenia Quiros-Roldan, Luisa Imberti
Publikováno v:
Biology of Sex Differences, Vol 12, Iss 1, Pp 1-11 (2021)
Abstract Background Coronavirus disease 2019 (COVID-19) severity seems to be influenced by genetic background, sex, age, and presence of specific comorbidities. So far, little attention has been paid to sex-specific variations of demographic, clinica
Externí odkaz:
https://doaj.org/article/de792193cb364a70a77611ff7adb7b65
Autor:
Virginia Quaresima, Cristina Scarpazza, Alessandra Sottini, Chiara Fiorini, Simona Signorini, Ottavia Maria Delmonte, Liana Signorini, Eugenia Quiros-Roldan, Luisa Imberti
Publikováno v:
Biology of Sex Differences, Vol 12, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/0fdabfa9dc9443139d4837d1bace1413
Autor:
Roberta Ghidoni, Simona Signorini, Laura Barbiero, Elena Sina, Paola Cominelli, Aldo Villa, Luisa Benussi, Giuliano Binetti
Publikováno v:
Neurobiology of Disease, Vol 22, Iss 2, Pp 357-362 (2006)
There is now considerable evidence that the gene encoding for tau protein (MAPT) is implicated in frontotemporal dementia (FTD). The role of MAPT haplotypes in neurodegenerative diseases has been suggested, but their contribution in familial dementia
Externí odkaz:
https://doaj.org/article/80e7e320d35b43f5be321524921e24a9
Autor:
Luisa Benussi, Roberta Ghidoni, Tiana Steinhoff, Antonella Alberici, Aldo Villa, Federica Mazzoli, Francesca Nicosia, Laura Barbiero, Laura Broglio, Enrica Feudatari, Simona Signorini, Ulrich Finckh, Roger M. Nitsch, Giuliano Binetti
Publikováno v:
Neurobiology of Disease, Vol 13, Iss 1, Pp 15-21 (2003)
CST3 is the coding gene for cystatin C (CysC). CST3 B/B homozygosity is associated with an increased risk of developing Alzheimer disease. We performed CysC analysis on human primary skin fibroblasts obtained from donors carrying A/A, A/B, and B/B CS
Externí odkaz:
https://doaj.org/article/30bfaa7317784c41b8c32651ef645024
Publikováno v:
Bioanalysis. 13:1781-1783
Autor:
Eugenia Quiros-Roldan, Simona Signorini, Luisa Imberti, Cristina Scarpazza, Ottavia M. Delmonte, Liana Signorini, Virginia Quaresima, Chiara Fiorini, Alessandra Sottini
Publikováno v:
Biology of Sex Differences, Vol 12, Iss 1, Pp 1-1 (2021)
Autor:
Giuliano Binetti, Laura Barbiero, Roberta Ghidoni, Paola Cominelli, Simona Signorini, Aldo Villa, Elena Sina, Luisa Benussi
Publikováno v:
Neurobiology of Disease, Vol 22, Iss 2, Pp 357-362 (2006)
There is now considerable evidence that the gene encoding for tau protein (MAPT) is implicated in frontotemporal dementia (FTD). The role of MAPT haplotypes in neurodegenerative diseases has been suggested, but their contribution in familial dementia
Autor:
Anna Paterlini, Giuliano Binetti, Francesca Nicosia, Antonella Alberici, Simona Signorini, Roberta Ghidoni, Laura Barbiero, Luisa Benussi
Publikováno v:
Experimental Cell Research. 308:78-84
Deposits of tau and alpha-synuclein are hallmarks of distinct neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Affinity chromatography experiments demonstrated a direct binding of the two proteins, and alpha-synuclein was shown to
Autor:
E.A Parati, Claudio Russo, Gennaro Schettini, Luisa Benussi, S.F Pagano, Simona Signorini, Francesca Nicosia, Laura Barbiero, G. Binetti, Federica Mazzoli, Roberta Ghidoni, Enrica Feudatari, Antonella Alberici
Publikováno v:
Experimental Neurology. 182:335-345
Brain deposition of the amyloid-beta protein (Abeta) is a frequent complication of Down's syndrome (DS) patients. Abeta peptide is generated by endoproteolytic processing of Abeta precursor protein by gamma and beta secretases. Recently a transmembra
Autor:
Francesco Castelli, Giampiero Carosi, Eugenia Quiros-Roldan, Simona Signorini, Carlo Torti, Andrea Patroni, Monica Airoldi
Publikováno v:
Journal of Clinical Laboratory Analysis. 15:43-46
The emergence of mutations encoding drug resistance is supposed to be a significant limitation to the clinical efficacy of inhibitor compounds directed against specific HIV‐1 enzymatic targets. We have used a commercial test (Visible Genetics Inc.,